Clinical Translation

A review from Qingdao University examines how flexible brain-computer interface electrodes are fabricated and optimized for signal recording and long-term stability. Mechanical mismatch between rigid electrodes and brain tissue may cause tissue damage and reduce recording stability during long-term implantation; flexible electrodes offer better mechanical compatibility. The review covers microelectromechanical systems, printing and transfer, laser processing, thermal drawing, and electrospinning, alongside deposition and surface modification for performance enhancement. It also identifies challenges in large-scale manufacturing, long-term stability, and the physical and clinical limitations of electrodes with different levels of invasiveness. This is a technology review, not a clinical efficacy study of a new device.

A prospective single-centre study involving Columbia University Medical Center found that 13 of 41 clinically unresponsive, critically ill patients with acute brain injury (32%) could control a brain-computer interface. The system analyzed EEG in real time and translated attempted movement into changes in sound. Clinical consciousness returned by discharge in 4/13 patients with BCI control versus 1/28 without it. At 12 months, 6/13 versus 2/28 met the study's definition of functional independence. BCI control was associated with subsequent recovery, but the findings do not show that device use caused recovery. The tested interface was one-way; bidirectional communication remains a future possibility.

The Guangdong Provincial Department of Science and Technology in southern China is accepting 2027 BCI project applications from October 23 to 5 p.m. on November 23, 2026, with departmental recommendations due by 5 p.m. on December 3. Required self-raised funding is generally at least 70% of total investment for directions requiring an enterprise lead and 50% for other directions.

The Shanghai Municipal Science and Technology Commission in eastern China is coordinating applications for the first batch of 2027 projects under the national brain science and brain-inspired research initiative. Online submission runs from November 4 to December 4, 2026, through the national science and technology management platform, with attachments uploaded as scans.

China’s NMPA UDI database lists Neuracle’s NEO-M and NEO-M Pro hand motor function compensation system models under registration certificate 国械注准20263120537, and K1014-25 and K1014-35 implantable EEG electrode kits under 国械注准20263120536. The descriptions identify the system’s implantable components, EEG transceiver, pneumatic glove and software.

A perspective paper proposes designing neural implants as functional tissues made of living cells, rather than solely as electrodes connecting to nerves. Called Cybertissue Neuroprosthetics, the concept aims for structural and functional integration with the host nervous system to support long-term neuromodulation and information exchange. It optionally incorporates minimal nanoelectronics, nanomaterials, or genetic modifications while seeking to reduce foreign materials and use cellular signaling mechanisms. The author proposes this approach to address interface deterioration during long-term implantation, but lifetime integration remains a goal, not an established device capability or clinical outcome.

A registered study that is not yet recruiting will compare a wearable brain-computer interface communication device with the eye-tracking devices already used by people with ALS. It plans to enroll 30 adults who use Tobii Dynavox or Smartbox eye-tracking devices. Each participant will try three options at home over 12 weeks: their own eye-tracking device and Cognixion ONE with either a head-worn augmented-reality display or a screen-based display. The main measure is the time participants voluntarily choose to use each option. Additional measures include communication speed, accuracy, and caregiver burden. No results are available. Cognixion ONE is investigational and is not FDA-approved or cleared for any medical use.

Brain-computer interfaces (BCIs) face human factors bottlenecks such as reliability and usability as they move toward real-world use, yet human factors engineering has mostly studied overt behavior and peripheral physiology rather than brain activity as a control input. This conceptual review proposes Human Factors Engineering for BCIs as an interdisciplinary direction, centered on user neurocognitive traits, brain-computer co-adaptation, multimodal feedback and context, with 3 core scientific questions and ethics, privacy and user rights as an overarching dimension.

Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life sciences fund, bringing its total raised since 2021 to $430 million. The company says it has completed more than 100 patient procedures at 18 medical institutions and holds FDA clearance for its Layer 7 Cortical Interface, a thin-film electrode array placed on the brain surface. It plans to use the money to expand clinical work, move Layer 7 through the next stages of FDA review and build out commercialization.

As brain-computer interfaces move toward clinical use, regulators, clinicians and developers need agreed rules on what counts as sufficient evidence. A new paper addresses how a clinical evidence framework for BCI can be built and applied. Only bibliographic metadata is publicly available so far, so the framework's components and intended uses cannot yet be verified.

KK Women's and Children's Hospital in Singapore has registered a clinical trial of brain-computer interface neurofeedback training (BCI-NFT) for children and adolescents aged 7 to 21 with acquired brain injury from causes including traumatic brain injury, stroke, encephalitis, brain tumors and epilepsy. The intervention group will complete 12 sessions of about 60 minutes each over 10 weeks, wearing a wireless EEG headband while interacting with neurofeedback computer games; the control group receives standard care first and then crosses over to training. A cohort of peers with no history of brain injury will provide normative EEG data. The trial plans to enroll 70 participants, with primary endpoint results expected in February 2028.

Fujian's science department and five other agencies issued a 2026-2030 BCI action plan on August 9, 2026, making the province the 11th in China with a dedicated BCI policy. It plans a cross-strait joint laboratory with Taiwanese research institutions and companies by 2027 and targets 30 innovative companies and a RMB 3 billion industry by 2030.

Hubei became the first Chinese province to publish BCI medical service prices on March 31, 2025, capping invasive implantation at RMB 6,552, and Wuhan hosted China's first BCI operation charged at the government guidance price in November 2025. The province has no dedicated BCI policy document, and its prices carry no insurance payment category.

Zhejiang became the first Chinese province to reimburse a BCI service when it covered non-invasive fitting fees under Category B insurance from September 1, 2025, limited to smart bionic prosthesis fittings. Its 18 industry-academia-research measures, dated July 16, 2026, cut review of qualifying Class II BCI devices to 40 working days and offer research hospitals up to RMB 8 million per project.

As of September 14, 2026, 11 of China's 31 provincial-level regions had issued dedicated BCI policy documents, but Hainan, Qinghai and Xinjiang had published BCI medical service prices without any industry plan. Hubei, Hunan, Chongqing and Henan have BCI initiatives but no dedicated documents, and 16 other regions show neither.

Training accurate BCI models depends on large, diverse EEG datasets, but that data is usually locked inside individual hospitals and labs, stored in inconsistent formats and restricted by privacy rules, which makes it hard to share. TrustBCI brings three functions into one platform: turning raw BCI datasets into assets that can be exchanged, using incentives to keep institutions contributing data, and letting users run computations without access to the raw records. The platform demonstrates two workflows, controllable data synthesis, which generates new datasets, and privacy-preserving query, which returns only query results. That suggests BCI models could be trained jointly across institutions without first pooling the data in one place.

Anhui issued a 2026-2030 BCI action plan on June 15, 2026 that sets its near-term milestones in 2028 rather than 2027 and frames every target as a minimum, including at least three approved invasive BCI clinical trials. Research leadership goes to the University of Science and Technology of China, with Hefei as the hub, Bengbu handling key components and Wuhu clinical translation.

Guangdong's provincial Party science and technology committee office issued a 2026-2030 BCI plan on June 5, 2026 that calls for 200 BCI hospital wards serving more than 500,000 patients cumulatively by 2030. The plan assigns invasive devices and signal decoding to Shenzhen and non-invasive systems to Guangzhou, and follows provincial BCI prices set nine months earlier, with implantation capped at RMB 6,600.

Tianjin's municipal government issued a 2026-2030 BCI action plan on May 26, 2026 that limits every numeric product target to non-invasive devices, aiming for more than ten in large-scale clinical use by 2030, while invasive products get a single unquantified approval goal. The plan also targets an industry fund cluster of more than RMB 10 billion by 2030.

Jiangsu's industry department and eight other agencies issued a BCI action plan in March 2026 that invites companies in hazardous chemicals, nuclear power, mining and electric power to pilot the technology first. Nearly all its numeric targets, including at least 20 registered medical products, fall in 2030, and a widely cited RMB 6,600 implant price appears only in a 2025 draft, not in the province's final pricing notice.

Jiangxi issued BCI support measures on November 26, 2025 that set no numeric targets but called for mutual recognition of clinical research ethics reviews, and its health commission followed on May 26, 2026 with guidance requiring participating sites to finish recognition reviews within 10 working days. Invasive projects for neurological or psychiatric treatment also need provincial expert review within 20 working days.

Shandong's health commission and 15 other agencies issued a BCI clinical translation plan on July 7, 2026, following a 2025 industry plan led by the provincial science department. The 14-measure plan sets up a clinical research alliance and a provincial clinical database, cuts review time for Class II devices to 90 working days, and targets more than 30 multicenter validation projects and a RMB 2 billion industry by 2028.

Sichuan's industry department and seven other agencies issued a BCI and human-machine interaction plan on May 12, 2025, targeting 3,000 invasive BCI operations a year by 2030 and the registration of three invasive and five non-invasive products by 2027. The province prices BCI services in five tiers by hospital grade, with implantation ranging from RMB 6,583 to RMB 4,389, all paid out of pocket.

Shanghai's science and technology commission issued a BCI action plan on January 10, 2025, pledging to help blind patients partially regain sight by 2030 and to have more than five invasive or semi-invasive products complete medical device type testing by 2027. The city's healthcare security bureau created three BCI service fee items in August 2025 but left prices to hospitals and explicitly excluded them from basic medical insurance payment.

Beijing issued China's first provincial-level brain-computer interface (BCI) action plan on January 7, 2025, setting every 2027 and 2030 target in terms of companies and platforms rather than output or revenue. The plan calls for three to five unicorns or would-be unicorns by 2027 and around 100 innovative small and medium-sized firms by 2030. On the payment side, Beijing prices invasive BCI implantation at RMB 7,980 per procedure and covers all three BCI service fees under Category A of basic medical insurance, limited to four hospitals.